Kyowa Hakko Kirin 2012 Results Boosted By NESP Flagship Drug
This article was originally published in PharmAsia News
Executive Summary
Despite a forecasted decrease in sales due to a 10% price revision, sales of Kyowa Hakko Kirin’s flagship renal anemia drug Nesp were ¥4.4 billion higher than expected at ¥58.1 billion, which was a 3% increase from the previous year.